Trial Profile
Incidence and Risk of Dystonia in Children and Adolescents Treated with Atomoxetine: A Retrospective Cohort Study
Status:
Not stated
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2017
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- 20 Sep 2017 New trial record
- 30 Aug 2017 Results presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management